Jon Napitupulu

Outlook Therapeutics resubmits LYTENAVA Bevacizumab to FDA with a 60-day review timeline after successful appeal of prior rejection.

ImmuCell posted preliminary first-quarter 2026 sales of $10.4 million, up 28.4% year over year, propelled by its Tri-Shield First...

Remedy Plan Therapeutics has appointed Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer as the company transitions...

Cue Biopharma will receive a $7.5 million preclinical milestone from Boehringer Ingelheim after BI selected the first compound from...

Nurix Therapeutics is moving its BTK degrader, bexobrutideg, onto a registrational track in relapsed/refractory chronic lymphocytic leukemia with an...

NovaBridge Biosciences reported year-end 2025 results and advanced two mid-stage assets: givastomig, a CLDN18.2 x 4-1BB bispecific antibody in...

NovaBridge Biosciences reported full-year 2025 results and set out a tighter, higher-stakes development agenda around two lead assets. In...

Nasdaq has approved, subject to closing conditions, the listing of the post-merger company formed by Coeptis Therapeutics and Z...

Marvel Biosciences has secured financial and strategic backing from 5 Horizons Ventures to initiate a Phase I study of...

AscellaHealth has been named to the Financial Times’ Americas’ Fastest Growing Companies 2026 list for the fourth consecutive year,...